Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2022-06-01

Clinical Trial Update: A Study of Durvalumab (MEDI4736) in Esophageal Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial of durvalumab in esophageal cancer has been completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Durvalumab (durvalumab)

Snippet

Sponsor: Shadia Jalal, MD | Conditions: Esophageal Cancer | Phase 2 | Status: COMPLETED | Results posted: 2022-06-01